Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway

Journal of Molecular and Cellular Cardiology

Volumn 44, Issue 3, 2008, Pages 477-485

  Herring, Neil ^a   Lokale, Michael N ^a   Danson, Edward J ^a   Heaton, Daniel A ^a   Paterson, David J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acetylcholine; Heart rate; Neuropeptide Y; Protein kinase C; Sinoatrial node

Indexed keywords

ACETYLCHOLINE; CALPHOSTIN; CARBACHOL; CHOLINE ACETYLTRANSFERASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENZYME INHIBITOR; NEUROPEPTIDE Y; NEUROPEPTIDE Y2 RECEPTOR; PROTEIN KINASE C;

ACETYLCHOLINE RELEASE; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; FEMALE; GUINEA PIG; HEART RATE; IMMUNOFLUORESCENCE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINUS NODE; VAGUS NERVE STIMULATION;

ACETYLCHOLINE; ANIMALS; ARGININE; BENZAZEPINES; BRADYCARDIA; CARBACHOL; CHOLINE O-ACETYLTRANSFERASE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FEMALE; GUINEA PIGS; HEART RATE; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; NEUROPEPTIDE Y; PROTEIN KINASE C; RECEPTORS, NEUROPEPTIDE Y; SIGNAL TRANSDUCTION; SINOATRIAL NODE; SULFONAMIDES; VAGUS NERVE;

CAVIA;

EID: 40649086450     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.10.001     Document Type: Article

References (43)

1. Cohn J.N., Levine T.B., Olivari M.T., Garberg V., Lura D., Francis G.S., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311 (1984) 819-823
2. Kleiger R.E., Miller J.P., Bigger Jr. J.T., and Moss A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 59 (1987) 256-262
3. La Rovere M.T., Bigger Jr. J.T., Marcus F.I., Mortara A., and Schwartz P.J. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351 (1998) 478-484
4. Nolan J., Batin P.D., Andrews R., Lindsay S.J., Brooksby P., and Mullen M. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 98 (1998) 1510-1516
5. Potter E.K. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y?. Neurosci Lett 54 2-3 (1985) 117-121
6. Smith-White M.A., Iismaa T.P., and Potter E.K. Galanin and neuropeptide Y reduce cholinergic transmission in the heart of the anaesthetised mouse. Br J Pharmacol 140 1 (2003) 170-178
7. Ilebekk A., Bjorkman J.A., and Nordlander M. Influence of endogenous neuropeptide Y (NPY) on the sympathetic-parasympathetic interaction in the canine heart. J Cardiovasc Pharmacol 46 4 (2005) 474-480
8. Ullman B., Franco-Cereceda A., Hulting J., Lundberg J.M., and Sollevi A. Elevation of plasma neuropeptide Y-like immunoreactivity and noradrenaline during myocardial ischaemia in man. J Intern Med 228 6 (1990) 583-589
9. Maisel A.S., Scott N.A., Motulsky H.J., Michel M.C., Boublik J.H., Rivier J.E., et al. Elevation of plasma neuropeptide Y levels in congestive heart failure. Am J Med 86 1 (1989) 43-48
10. Hulting J., Sollevi A., Ullman B., Franco-Cereceda A., and Lundberg J.M. Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24 2 (1990) 102-108
11. Lundberg J.M., Hua X.Y., and Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand 121 4 (1984) 325-332
12. Potter E. Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett 83 1-2 (1987) 101-106
13. Pardini B.J., Lund D.D., and Puk D.E. Sites at which neuropeptide Y modulates parasympathetic control of heart rate in guinea pigs and rats. J Auton Nerv Syst 38 2 (1992) 139-145
14. Potter E.K. Cardiac vagal action and plasma levels of neuropeptide Y following intravenous injection in the dog. Neurosci Lett 77 2 (1987) 243-247
15. Smith-White M.A., Wallace D., and Potter E.K. Sympathetic-parasympathetic interactions at the heart in the anaesthetised rat. J Auton Nerv Syst 75 2-3 (1999) 171-175
16. Smith-White M.A., Hardy T.A., Brock J.A., and Potter E.K. Effects of a selective neuropeptide Y Y2 receptor antagonist, BIIE0246, on Y2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132 4 (2001) 861-868
17. Smith-White M.A., Herzog H., and Potter E.K. Role of neuropeptide Y Y(2) receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept 103 2-3 (2002) 105-111
18. Sosunov E.A., Anyukhovsky E.P., and Rosen M.R. Effects of exogenous neuropeptide Y on automaticity of isolated Purkinje fibers and atrium. J Mol Cell Cardiol 28 5 (1996) 967-975
19. Michel M.C. Receptors for neuropeptide Y: multiple subtypes and multiple second messengers. Trends Pharmacol Sci 12 10 (1991) 389-394
20. Balasubramaniam A.A. Neuropeptide Y family of hormones: receptor subtypes and antagonists. Peptides 18 3 (1997) 445-457
21. Herring N., Golding S., and Paterson D.J. Pre-synaptic NO-cGMP pathway modulates vagal control of heart rate in isolated adult guinea pig atria. J Mol Cell Cardiol 32 (2000) 1795-1804
22. Herring N., and Paterson D.J. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol 535 2 (2001) 507-518
23. Herring N., Zaman J.A., and Paterson D.J. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway. Am J Physiol Heart Circ Physiol 281 6 (2001) H2318-H2327
24. McCullough L.A., Egan T.M., and Westfall T.C. Neuropeptide Y inhibition of calcium channels in PC-12 pheochromocytoma cells. Am J Physiol 274 5 Pt 1 (1998) C1290-C1297
25. Heredia M.P., Fernandez-Velasco M., Benito G., and Delgado C. Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br J Pharmacol 135 7 (2002) 1701-1706
26. Wang H., and Morris J.F. Presence of neuronal nitric oxide synthase in the suprachiasmatic nuclei of mouse and rat. Neuroscience 74 (1996) 1059-1068
27. Sears C.E., Choate J.K., and Paterson D.J. Inhibition of nitric oxide synthase slows heart rate recovery from cholinergic activation. J Appl Physiol 84 (1998) 1596-1603
28. Wetzel G.T., and Brown J.H. Relationships between choline uptake, acetylcholine synthesis and acetylcholine release in isolated rat atria. J Pharmacol Exp Ther 226 2 (1983) 343-348
29. Dumont Y., Cadieux A., Doods H., Pheng L.H., Abounader R., Hamel E., et al. BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist. Br J Pharmacol 129 6 (2000) 1075-1088
30. Kobayashi E., Nakano H., Morimoto M., and Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159 2 (1989) 548-553
31. Herbert J.M., Augereau J.M., Gleye J., and Maffrand J.P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 172 3 (1990) 993-999
32. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 265 9 (1990) 5267-5272
33. Schwertfeger E., Klein T., Vonend O., Oberhauser V., Stegbauer J., and Rump L.C. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol 369 5 (2004) 455-461
34. Yu X.C., Wang H.X., Pei J.M., and Wong T.M. Anti-arrhythmic effect of kappa-opioid receptor stimulation in the perfused rat heart: involvement of a cAMP-dependent pathway. J Mol Cell Cardiol 31 10 (1999) 1809-1819
35. Mielke M., Paterson D.J., Sang A.E., Radda G.K., and Clarke K. The mechanism underlying the positive inotropic effect of angiotensin II in the isolated perfused rabbit heart: a 31P NMR study. Int J Biochem Cell Biol 35 6 (2003) 984-991
36. 3H]-noradrenaline. Br J Pharmacol 94 3 (1988) 713-720
37. Cho H., Youm J.B., Earm Y.E., and Ho W.K. Inhibition of acetylcholine-activated K(+) current by chelerythrine and bisindolylmaleimide I in atrial myocytes from mice. Eur J Pharmacol 424 3 (2001) 173-178
38. Seebeck J., Schmidt W.E., Kilbinger H., Neumann J., Zimmermann N., and Herzig S. PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones. Naunyn Schmiedebergs Arch Pharmacol 354 4 (1996) 424-430
39. Toth P.T., Bindokas V.P., Bleakman D., Colmers W.F., and Miller R.J. Mechanism of presynaptic inhibition by neuropeptide Y at sympathetic nerve terminals. Nature 364 6438 (1993) 635-639
40. Hirning L.D., Fox A.P., and Miller R.J. Inhibition of calcium currents in cultured myenteric neurons by neuropeptide Y: evidence for direct receptor/channel coupling. Brain Res 5:532 1-2 (1990) 120-130
41. Wiley J.W., Gross R.A., Lu Y.X., and Macdonald R.L. Neuropeptide Y reduces calcium current and inhibits acetylcholine release in nodose neurons via a pertussis toxin-sensitive mechanism. J Neurophysiol 63 6 (1990) 1499-1507
42. McDonald R.L., Vaughan P.F., Beck-Sickinger A.G., and Peers C. Inhibition of Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by neuropeptide Y and a novel cyclic neuropeptide Y analogue. Neuropharmacology 34 11 (1995) 1507-1514
43. Danson E.J., Zhang Y.H., Sears C.E., Edwards A.R., Casadei B., and Paterson D.J. Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression. Cardiovasc Res 67 4 (2005) 613-623